Gerresheimer is a profitable sustainable growth company
Gerresheimer’s dynamic growth in the financial year 2023 is the result of the systematic implementation of the formula g strategy process. With a highly customer-oriented approach, innovation, and a focus on top quality, our company has continuously improved its competitiveness, proved its resilience, and generated sustainable profitable growth. Growth drivers such as high-value solutions for biopharmaceuticals, medical devices, and containment solutions contribute to the unique dynamic.
The global drug pipeline is dominated by injectables. Injection solutions are also the most widely used means of administering biopharmaceutics They account for around 90% of the global drug pipeline. The market for biopharmaceuticals is growing at an average of 15% a year, significantly faster than the market as a whole.
Our broad product portfolio enables us to address global megatrends and win orders for new innovative drugs, particularly biopharmaceuticals such as drugs based on the peptide hormone GLP-1 (glucagon-like peptide 1) for the treatment of obesity.
With the market set to be worth an estimated USD 80bn by 2030, GLP-1 typifies the huge potential of biopharmaceutical drugs and offers us unique opportunities for further profitable growth.
Further stories